|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NTM |
Gene summary for NTM |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NTM | Gene ID | 50863 |
| Gene name | neurotrimin | |
| Gene Alias | CEPU-1 | |
| Cytomap | 11q25 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q9P121 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 50863 | NTM | P4T-E | Human | Esophagus | ESCC | 7.93e-07 | 2.98e-01 | 0.1323 |
| 50863 | NTM | P9T-E | Human | Esophagus | ESCC | 4.01e-04 | 2.41e-01 | 0.1131 |
| 50863 | NTM | P11T-E | Human | Esophagus | ESCC | 1.92e-17 | 1.19e+00 | 0.1426 |
| 50863 | NTM | P16T-E | Human | Esophagus | ESCC | 2.53e-03 | 6.31e-02 | 0.1153 |
| 50863 | NTM | P19T-E | Human | Esophagus | ESCC | 1.17e-11 | 1.65e+00 | 0.1662 |
| 50863 | NTM | P24T-E | Human | Esophagus | ESCC | 9.20e-06 | 3.08e-01 | 0.1287 |
| 50863 | NTM | P30T-E | Human | Esophagus | ESCC | 4.84e-02 | 2.03e-01 | 0.137 |
| 50863 | NTM | P32T-E | Human | Esophagus | ESCC | 4.30e-10 | 4.37e-01 | 0.1666 |
| 50863 | NTM | P42T-E | Human | Esophagus | ESCC | 2.79e-04 | 2.38e-01 | 0.1175 |
| 50863 | NTM | P44T-E | Human | Esophagus | ESCC | 1.46e-07 | 3.83e-01 | 0.1096 |
| 50863 | NTM | P47T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.19e-01 | 0.1067 |
| 50863 | NTM | P56T-E | Human | Esophagus | ESCC | 1.16e-08 | 9.05e-01 | 0.1613 |
| 50863 | NTM | P89T-E | Human | Esophagus | ESCC | 1.41e-38 | 1.70e+00 | 0.1752 |
| 50863 | NTM | RNA-P10T1-P10T1-1 | Human | Lung | AIS | 1.16e-02 | 1.11e+00 | -0.0764 |
| 50863 | NTM | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.22e-02 | 6.02e-01 | -0.1408 |
| 50863 | NTM | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.93e-23 | 1.27e+00 | -0.2116 |
| 50863 | NTM | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.51e-14 | 1.27e+00 | -0.1941 |
| 50863 | NTM | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 5.62e-17 | 1.34e+00 | -0.2107 |
| 50863 | NTM | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 4.48e-22 | 1.17e+00 | -0.2119 |
| 50863 | NTM | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 6.34e-11 | 1.61e+00 | -0.0238 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
| GO:00070593 | Esophagus | HGIN | chromosome segregation | 71/2587 | 346/18723 | 3.47e-04 | 5.62e-03 | 71 |
| GO:00070518 | Esophagus | HGIN | spindle organization | 42/2587 | 184/18723 | 6.07e-04 | 8.49e-03 | 42 |
| GO:00182089 | Esophagus | HGIN | peptidyl-proline modification | 17/2587 | 58/18723 | 1.64e-03 | 1.82e-02 | 17 |
| GO:00064798 | Esophagus | HGIN | protein methylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
| GO:00082138 | Esophagus | HGIN | protein alkylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:00165718 | Esophagus | ESCC | histone methylation | 89/8552 | 141/18723 | 2.17e-05 | 1.87e-04 | 89 |
| GO:0031365 | Esophagus | ESCC | N-terminal protein amino acid modification | 21/8552 | 30/18723 | 6.17e-03 | 2.27e-02 | 21 |
| GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
| GO:00182084 | Liver | Cirrhotic | peptidyl-proline modification | 26/4634 | 58/18723 | 6.65e-04 | 5.04e-03 | 26 |
| GO:00070514 | Liver | Cirrhotic | spindle organization | 62/4634 | 184/18723 | 3.88e-03 | 2.10e-02 | 62 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NTM | SNV | Missense_Mutation | novel | c.49N>C | p.Val17Leu | p.V17L | Q9P121 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| NTM | SNV | Missense_Mutation | c.637N>T | p.Arg213Trp | p.R213W | Q9P121 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD | |
| NTM | SNV | Missense_Mutation | c.56N>A | p.Gly19Glu | p.G19E | Q9P121 | protein_coding | tolerated(0.34) | benign(0.118) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| NTM | insertion | Frame_Shift_Ins | novel | c.336_337insCCCTCTGATGGCTGCTGTCGTCTCTCAGTCCC | p.Tyr113ProfsTer38 | p.Y113Pfs*38 | Q9P121 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| NTM | deletion | Frame_Shift_Del | rs746798762 | c.3delN | p.Val3_?1 | p.V3_?1 | Q9P121 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NTM | SNV | Missense_Mutation | novel | c.739N>T | p.Ala247Ser | p.A247S | Q9P121 | protein_coding | deleterious(0.02) | probably_damaging(0.918) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NTM | SNV | Missense_Mutation | c.260N>A | p.Arg87His | p.R87H | Q9P121 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NTM | SNV | Missense_Mutation | c.389N>C | p.Leu130Pro | p.L130P | Q9P121 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NTM | SNV | Missense_Mutation | rs752839570 | c.631N>A | p.Val211Met | p.V211M | Q9P121 | protein_coding | deleterious(0) | possibly_damaging(0.886) | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NTM | SNV | Missense_Mutation | c.529N>A | p.Val177Ile | p.V177I | Q9P121 | protein_coding | tolerated(0.21) | benign(0.3) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |